Drug Profile
Ghrelin and growth hormone combination therapy - TheraSource
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator TheraSource
- Class Anti-infectives; Growth hormones; Peptide hormones
- Mechanism of Action Ghrelin receptor agonists; Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Sepsis
Highest Development Phases
- No development reported Sepsis
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Sepsis in USA (SC, Injection)
- 04 Aug 2016 Ghrelin and growth hormone combination therapy - TheraSource is available for licensing as of 04 Aug 2016. http://therasourceinc.com/